Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05813288 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
A Phase 3 study, sponsored by Areteia Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 654
- Enrollment target
NCT05813288 is a Phase 3 study that was terminated before completion, run by Areteia Therapeutics. The registered enrollment target is 654 participants.
The verdict
NCT05813288, a Phase 3 study, was terminated before completion, sponsored by Areteia Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 654 participants
- Enrollment target
Study Summary
The objective of this clinical study is to investigate the safety, tolerability, and efficacy of dexpramipexole in participants with inadequately controlled severe eosinophilic asthma.
Interventions
- DRUG Placebo
- DRUG Dexpramipexole Dihydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 654 participants |
| Start Date | 2023-03-27 |
| Est. Completion | 2025-12-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05813288
The ClinicalTrials.gov registry entry for NCT05813288 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 654 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Areteia Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05813288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05813288 about?
NCT05813288 is a clinical study titled "A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)". The objective of this clinical study is to investigate the safety, tolerability, and efficacy of dexpramipexole in participants with inadequately controlled severe eosinophilic asthma.
What is the current status of trial NCT05813288?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 654 participants. The study started on 2023-03-27. Estimated completion is 2025-12-08.
What interventions are being tested in trial NCT05813288?
The interventions under investigation include: Placebo (DRUG), Dexpramipexole Dihydrochloride (DRUG).
Who is sponsoring clinical trial NCT05813288?
This trial is sponsored by Areteia Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.